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Abstract—In this work, we show the realization of a fully-im-
plantable device for monitoring free-moving small animals. The
device integrates a microfabricated sensing platform, a coil for
power and data transmission and two custom designed integrated
circuits. The device is intended to be implanted in mice, free to
move in a cage, to monitor the concentration of metabolites. We
show the system level design of each block of the device, and we
present the fabrication of the passive sensing platform and its em-
ployment for the electrochemical detection of endogenous and ex-
ogenous metabolites. Moreover, we describe the assembly of the
device to test the biocompatibility of the materials used for the
microfabrication. To ensure biocompatibility, an epoxy enhanced
polyurethane membrane was used to cover the device. We proved
through an in-vitro characterization that the membrane was ca-
pable to retain enzyme activity up to 35 days. After 30 days of im-
plant in mice, in-vivo experiments proved that the membrane pro-
motes the integration of the sensor with the surrounding tissue, as
demonstrated by the low inflammation level at the implant site.
Index Terms—Biocompatible packaging, biosensors, chrono-
amperometry, cyclic voltammetry, implantable electronics,
powering system.
I. INTRODUCTION
E LECTROCHEMICAL sensors for continuous monitoringof glucose and lactate are already in the market [1], more-
over, first prototypes of fully implantable glucose sensors have
been validated up to 8 months in mice [2] and up to one year in
pigs [3]. The continuous monitoring of endogenous molecules
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(e.g., glucose, lactate, ATP) in mice, enables understanding of
animal model metabolism in translational medicine [4]. The de-
velopment of an implantable device for monitoring also exoge-
nous substances, such as drugs, would represent a big step to-
wards personalized medicine, because it would enable the in-
dividual adjustment of the drug dosage and, therefore, it would
increase the accuracy and efficacy of the treatment and reduce
dangerous adverse drug reactions, especially for patients with
critical or chronic conditions [5].
Electrochemical sensors are the ideal devices for these ap-
plications by providing rapid, accurate and quantitative detec-
tion of analytes with an inexpensive and simple to use set-up
[5]. An implantable device capable of monitoring multiple sub-
stances should contain an array of sensors with enough sensi-
tivity to monitor drugs and metabolites within the therapeutic
range. The sensor sensitivity is improved by using nanostruc-
tured materials. In our previous works we proved that carbon
nanotubes (CNTs) clearly provide great advantages when used
in electrochemical biosensing [6], in terms of sensitivity and de-
tection limit. However, since CNTsmay be potentially toxic, the
biocompatibility of devices incorporating nanomaterials needs
to be investigated. The biocompatibility and the sensor stability
in time are other fundamental issues for implantable devices:
the sensor should be well tolerated by the host and cause a lim-
ited foreign body reaction, and at the same time the contact with
biological fluids should not significantly affect sensor perfor-
mances [7]. Moreover, an implantable device should contain the
required electronics in order to supply enough power for the
biosensor and for the data transmission. It is therefore neces-
sary to power the system externally because available batteries
in the market are bulky, heavy, they would need replacement,
and because batteries would increase the dimensions of the final
device.
The present work focuses on the design, fabrication, charac-
terization and packaging of a fully-implantable device for the
continuous monitoring of drug and metabolite concentration in
mice. Small animal models are increasingly being used in the
first phase of clinical trials for drug development. The living
conditions of these animals are of primary importance because
the stress level can affect the measurement results. This means
that the animal must be in a comfortable environment and ca-
pable to freely move. Therefore, the final aim of our work is
to monitor the animal in a living space, such as a cage, and
the power must be continuously transferred to the implantable
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system according to the position of the animal [8]. The fully-
implantable device consists of: 1) a passive sensing platform,
2) integrated circuits (ICs) to perform electrochemical measure-
ments and 3) a coil for power and data transmission. The device
is intended to be implanted subcutaneously in the back of mice.
In the recent literature, a number of integrated systems for
biomedical implants have been reported. However the compar-
ison with our system is not so straightforward, because some
works focus on different applications [9], [10], some works
do not target any specific applications [11], [12], other works
present measurements of a single metabolite [13], or have
batteries [14].
In the first part of the result section (Section II) we present
the design and fabrication of each single block. The materials
and methods are reported in Section III. In the Section IV,
we show the characterization of the passive sensing platform,
obtained with the commercial potentiostat, and also some
measurements performed with the autonomous system that
consists on the integration of the passive platform, ICs and the
powering system described in Section II. In the Section V, we
show the assembly of these components and the use of an inno-
vative biocompatible packaging based on an epoxy enhanced
polyurethane membrane. After an in-vitro characterization, we
finally demonstrated the biocompatibility of the chip and the
membrane with in-vivo biocompatibility tests, by implanting
the devices in mice for 30 days.
II. IMPLANTABLE BIOSENSOR: DESIGN AND FABRICATION
In this section we present an overview of the implantable
biosensor system design. We first show the design of the con-
trol and readout IC, the transmitter, of the power management
IC and of the inductive link, with details about the design of the
remote powering system and fabrication of the coils. In the first
three subsections, details on the design and the performance pa-
rameters are presented for each block. Finally, in the last subsec-
tion we describe the design and fabrication steps for the passive
sensing platform.
A. Application Scenario
Since the stress level changes the measurement result, the an-
imal needs to be in a natural environment and to move freely.
Therefore, the animal must be monitored in a living space and
the power must be transferred to the implantable system contin-
uously. We decided to monitor the animal free to move inside a
cage used in the laboratory. And an intelligent remote powering
(IRPower) system is proposed for continuous long-term moni-
toring and to deliver the power efficiently though an optimized
inductively coupled power link. Fig. 1 shows the scenario of the
implantable sensor system for the freelymoving animal. The IR-
Power system consists of detection and movement blocks [15],
[16]. The detection block is used to find and track the animal in
the living space. The magnetic field sensors are used to find and
track the permanent magnet which is implanted in the animal.
The movement block has X and Y rails to move the powering
coil to concentric position with the implanted coil where the ef-
ficient power transfer is assured. The rails move at maximum
speed of 30 cm/s which is sufficient to track a mouse in a living
space.
Fig. 1. Scheme of the implantable sensor system for a freely moving animal.
B. Integrated Circuits and Communication Protocol Design
Fig. 2 shows the block diagram of the implantable biosensor
system. The power is transferred over an optimized remote pow-
ering link which is driven by an efficient class-E power ampli-
fier. The overall power efficiency of the inductive link is 21% in-
cluding the drain efficiency of the power amplifier.The induced
voltage at the implantable system is proportional to the remote
powering frequency. On the other hand, the penetration depth
of the power in the body decreases with frequency. Therefore,
an optimal frequency is necessary [17]. An ISM band which is
13.56 MHz is chosen for the wireless power transmission. A
second channel is preferred for a reliable data transmission due
to the moving animal. When the animal moves, the coupling be-
tween the coils changes and the received power at the implant
changes. Using the same inductive link for power and communi-
cation does not allow a reliable data transmission. Accordingly,
the data is transmitted over a second channel at 869 MHz by an
on-off keying (OOK) transmitter.
The induced voltage is converted to a DC voltage with more
than 80% of power efficiency by a passive full-wave rectifier.
A low-drop out (LDO) voltage regulator follows the rectifier
to create 1.8 V supply voltage for the bio-sensor system. The
PSRR value of the voltage regulator is more than 60 dB at
27.12 MHz. The reference voltage for the voltage regulator is
generated on chip by a fully CMOS voltage generation circuit.
The regulated voltage is given to the waveform generator and
the readout and control circuits as the supply voltage. The wave-
form generator is a mixed-mode circuit to generate different
voltage waveforms to control cyclic voltammetry (CV) and pro-
grammable constant voltage levels to enable chronoamperom-
etry (CA), by using a single mixed-signal circuit. The control
and readout circuit applies this waveform to the biosensor and
measures the resulted sensor current as shown in Fig. 2. This
block controls and reads out the sensor array as well as pH
and temperature sensors for calibration purpose. It consists of
programmable gain amplifiers and a second-order sigma delta
analog to digital converter as well as a temperature readout cir-
cuit. An on-chip multiplexer decides which sensing site should
be connected to the readout circuit. The digital output of the
converter goes through an 8 b/10 b encoding for DC-balancing
and to prevent long sequence of similar logic in communica-
tion. It consumes 500 from a 1.8 V supply voltage. More
information about the design of the readout and control IC can
be found in [18]. We have also developed another type of CA
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Fig. 2. Block diagram of the implantable biosensor system.
Fig. 3. Timing schedule for the measurements.
and CV readout circuit based on current to frequency conversion
[19]. A sample timing schedule for the measurements is shown
in Fig. 3. The control and readout circuit has been designed to
run the measurements according to this schedule. It measures
three different drugs out of three different sensing sites by CV
and a single metabolite by CA on the fourth sensing site. Prior to
these measurements, pH and the temperature of the solution are
measured. It is well-known that changes in pH or temperature
could affect the current response in both CV and CA measure-
ments [20]. Thus, the control over pH and temperature enables
to correct eventual changes in the current response, during the
data post-processing. More information about the design of the
readout and control IC can be found in [18], [21].
Transmitter is one of the most power hungry blocks in a
system. Therefore, a low-power transmitter is essential to re-
duce the power consumption. OOK transmitter is a well-known
method for data communication in implantable biomedical sys-
tems [22]. Although the transmitter saves energy during trans-
mitting bit “0”, the transmitter still consumes high power due
to the power amplifier. Accordingly, the proposed OOK trans-
mitter excludes the power amplifier for short range communica-
tion and consists of a free running LC oscillator which reduces
the overall power consumption of the biosensor system. In addi-
tion, the transmitter’s inductor is designed as a loop antenna for
short-range communication. The data is received by a custom
design receiver at 869 MHz, 40 cm away. The transmitter con-
sumes 180 at 1.8 V supply voltage, and it allows a reliable
data communication with a data rate of 1.5 Mbps.
An optimized inductively coupled power link is designed for
an efficient power delivery. The load of the biosensor system
can vary. Therefore, the required power at the implantable
Fig. 4. Remote powering signals and power feedback data for power
adaptation.
system can change. Moreover, the coupling between the pow-
ering and implant coils may change due to the movement of
the animal and hence the received power at the implantable
system can change. Accordingly, a power adaptation technique
is used to transmit sufficient power to the implantable system:
the power level at the implantable system is transmitted to
the external unit. The supply voltage of the power amplifier is
adjusted and hence the transmitted power changes according
to the power feedback data. Fig. 4 shows the remote powering
signals and power feedback data for power adaptation. When
the implant coil moves closer to the center of the powering
coil, the received power by the implantable system increases.
Therefore, the rectifier voltage increases. The transmitted
power level is adjusted by tracking the rectifier voltage and
transmitting power feedback data to the external base station.
The implantable circuits have been designed and realized in
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TABLE I
INDUCTIVE-LINK PERFORMANCE COMPARISON
Fig. 5. Optimized power link.
180 nm technology. More information about the power man-
agement and transmitter can be found in [8], [23]. The overall
power consumption of the system is less than 1.6 mW. In the
Table I, the performance of the presented inductive-link system
are compared with other similar system existing in literature.
C. Coil Design and Fabrication
The coupling of the coils is a critical parameter to increase the
power transfer efficiency especially when the distance between
the coils is large. To obtain the optimal remote powering link,
we proposed a combination of two approaches: analytical equa-
tions and a 3-D high frequency simulation software [17]. In the
optimization method, each geometric parameter of the coils was
swept to obtain the optimal coil pair. Accordingly, the lumped
model parameters of the remote powering link were extracted
by using analytical equations and a field solver software. The
power transfer efficiency of the remote powering link was calcu-
lated and the geometric parameters of the coils were character-
ized in 3-D electromagnetic field simulation software (HFSS).
Finally, the coils were produced on printed circuit board (PCB)
for reliability and reproducibility and characterized for opera-
tion frequency. The materials used were copper on a FR4 sub-
strate. Fig. 5 shows the optimized inductively coupled power
link, where the implanted coil is showed on the top of the pow-
ering coil for a better comparison. The sizes of the powering and
implanted coils are 80 80 mm and 12 12 mm, respectively,
and the power transfer efficiency is limited over 30 mm distance
[16].
Fig. 6. Photographs of the microfabricated platform (center), with the three
geometries for the working electrode (WE), the pads for integration with ICs,
the pH sensor and the temperature sensor.
D. Design and Fabrication of the Passive Chip
The microfabrication of the passive chip was realized with
a two-masks process flow. Details on the process flow can be
found in [27]. The design of the passive chip was done under
the constraints given by the compatibility with the other com-
ponents. The platform measures 12 11 mm in order to fit the
size of the coil (12 12 mm) and the wire bonding. Fig. 6
shows the photograph of the passive chip with the main struc-
tures. The platform hosts an array of four independent cells in
the three-electrode configuration: a working electrode (WE), a
counter electrode (CE) and a reference electrode (RE), all made
in Pt. Working electrodes were realized in three different ge-
ometries (diameter of 500 , 1 mm and 1.2 mm). The main
advantage behind the design of an array of independent sensors
is the possibility to perform multiplexed measurements of drugs
or metabolites.
A pH sensor and a temperature sensor were fabricated in Pt.
The pH sensor has been designed in two versions: one has a WE
with a 300 diameter (showed in Fig. 6), while the second
version has a squared WE of . Both versions
are based on an anodic iridium oxide film in order to compare
themwith our previous results [27]. The resistive thermal device
(RTD) consists of a Pt wire (4 nm width and 93 mm length) with
an average resistivity of 34 at 20 , compatible with the
power constraints. The design of a sensing platform for electro-
chemical measurement, combined with the presence of a pH and
a temperature sensor, is a strategy to optimize the sensing per-
formance in different physiological conditions, since changes in
pH and temperature can affect the sensor specificity [20]. In the
640 IEEE TRANSACTIONS ON BIOMEDICAL CIRCUITS AND SYSTEMS, VOL. 8, NO. 5, OCTOBER 2014
next paragraphs we will show that our microfabricated platform
can be exploited for the monitoring of multiple substances.
III. MATERIALS AND METHODS
A. Passive Chip Microfabrication
Microfabrication was realized at the EPFL Centre of Micro-
nano Technology (CMI). Silicon wafers with 500 nm of native
oxide were chosen as substrate. Chip metalization was realized
by evaporation of 10 nm of Ti, followed by 100 nm of Pt. Metal
passivation was made via atomic layer deposition of ,
followed by dry etching with Argon Ion Milling. Details on the
microfabrication can be found in [27].
B. Sensors Functionalization and Membrane Deposition
1) Chemicals: Multi-walled carbon nanotubes (MWCNTs,
10 nm diameter and length) with 5% -COOH
groups content, were purchased as a powder (90% purity) from
DropSens (Spain). For the drop-cast deposition, a 1 mg/ml
solution of MWCNTs, prepared in chloroform, was sonicated
for 3 h to obtain a homogeneous suspension [28]. For elec-
trodeposition, MWCNTs in powder were dispersed in chitosan
(0.7% w/v, pH 5) and then sonicated for 3 h to obtain a 8 mg/ml
solution. All experiments were carried out in a 100 mM phos-
phate buffered saline solution (PBS, pH 7.4) as supporting
electrolyte.
Glucose oxidase (GOx) from Aspergillus Niger was pur-
chased from Roche in lyophilizate powder and dissolved in a
100 mM PBS (pH 5.86). -glucose was purchased from
Sigma-Aldrich (Switzerland) in powder and dissolved in in
Milli-Q water. Etoposide (ETO) and mitoxantrone (MTX) were
purchased as a powder from Sigma-Aldrich. Due to their low
solubility in water, ETO andMTX solutions at different concen-
tration were prepared by dissolving them in Dimethyl sulfoxide
(from Sigma Aldrich) before storage at room temperature.
For the pH sensor, a solution of Iridium(IV) chloride hydrate
(99.9% metals basis, from Sigma Aldrich), (30%), Ox-
alic acid dihydrate (98%, from Sigma Aldrich), and Potassium
carbonate anhydrous (99%, from Alfa Aesar) was prepared for
the deposition of the Iridium Oxide film (IrOx), as reported in
[29].
2) Electrode Preparation and Functionalization: We per-
formed electrochemical measurements with both carbon paste
screen-printed electrodes (SPEs, model DRP-110, DropSens)
and the microfabricated passive platform. The working elec-
trode of SPEs was nanostructured with 30 MWCNTs
as reported in [28]. For the microfabricated platform, some
working electrodes were functionalized by electrodeposition of
a chitosan/MWCNT dispersion 8 mg/ml, by applying a fixed
potential of 1.5 V for 2400 s [27]. A 15 mg/ml solution of GOx
was drop cast on some working electrodes and stored overnight
at 4 . All the samples were freshly prepared and used the
same day. When not in use, electrodes were stored at 4 .
For the measurements in CV, the electrodes were used without
modifications.
For the pH sensor we used a squared electrode
in a passive platform that we previously realized
[27]. A layer of IrOx was created on the electrode surface by
galvanostatic deposition, by applying a constant current of
0.9375 for 500 s. After a stabilization in PBS pH 7.4 for
2 days to reduce potential drift, the electrodes were tested for
pH sensing.
C. Electrochemical Measurements
To verify the passive sensing plaform, electrochemical mea-
surements were performed using an Autolab electrochemical
workstation (Metrohm, Switzerland). Electrodes were tested for
glucose sensitivity with CA at 650 mV. The sensors were
first dipped in a 100 mM PBS solution (pH 7.4), under stir-
ring conditions, then conditioned for 1 h at 650 mV and then
tested against repeated injections of glucose. CV was used to
identify the oxidation/reduction peaks of ETO and MTX. CV
was performed at room temperature under aerobic conditions
by applying a triangular waveform voltage in the range between
600 mV and 800 mV versus Pt, with scan rate of 20 mV/s.
After an initial conditioning in PBS, drops of 200 of ETO
or MTX solutions were added at the right concentration. CV
measurements were also performed with our autonomous mi-
crosystem that consists on the integration of: (i) the inductive
coil; (ii) the power management IC; (iii) the interface IC to con-
trol and readout the biosensor; and (iv) the biosensor.
pH was computed averaging the open circuit potential (OCP)
in a time window of around 120 by continuously changing the
pH of the buffer solution by means of an external pH meter
(from VWR). An external reference electrode (double junction
in Ag|AgCl) was used in order to have stable and reproducible
measurements. For the temperature sensor, a True RMS Mul-
timeter 37XR (Wavetek Meterman) was connected to our plat-
form to measure the changes in resistivity.
Sensitivity and limit of detection (LOD) are the key parameter
used to evaluate the sensing performances. Sensitivity per unit
area was computed from the slope of the straight line obtained
by plotting the current steps versus glucose or drug concentra-
tion. The LOD was computed as three times the signal-to-noise
ratio according to the expression , where
is the standard deviation of the blank measurements, is the
sensitivity, and is a parameter accounting for the confidence
level ( , 2, or 3 corresponds to 68.2%, 95.4%, or 99.6% of
statistical confidence), according to [30].
D. Integrated Device Assembly
The epoxy adhesive (EP42HT-2Med system) was used to as-
sembly the electronic component in the integrated device. The
interconnections between the pads of the passive chip and elec-
tronic components were realized with Al wire bonding and were
protected with a glob top protection of 0.3 mm. All the edges of
the device were rounded with a milling machine. Two subse-
quent 5 layers of Parylene C were deposited by chemical
vapor deposition using a Comelec C-30-S Parylene Deposition
System. Parylene C was used to cover the whole device but not
the electrode array that needs to be in contact with fluids. Fig. 7
shows the components of the implantable device. Finally, the
electrodes were functionalized with MWCNTs and the device
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Fig. 7. Scheme of the integrated device assembly.
was covered with three layers of a biocompatible membrane as
described in the next section.
E. Biocompatible Membrane
For the biocompatible membrane, a homogeneous solu-
tion was obtained by mixing 125 mg of an epoxy adhesive
(EP42HT-2Med system), purchased by Master Bond (Hack-
ensack, USA) as a certified biocompatible two-components
adhesive, 112.5 mg of Polyurethane (PU, Sigma Aldrich),
12.5 mg of the surfactant agent Polyethylene glycol ether
(Brij 30, Sigma Aldrich), for 10 ml of Tetrahydrofuran (THF,
Sigma Aldrich) used as solvent.
The deposition method of the biocompatible membrane is
known as dip coating and it consists of a quick immersion of
the sensor in the membrane solution. Subsequent depositions
were applied at 2 h intervals and then the sensors were stored
overnight at room temperature. A fast curing at high tempera-
ture (2 h at 80 ) is needed to ensure the biocompatibility of the
resin. After this process the sensors were again kept overnight
at room temperature, and then stored in PBS one day for mem-
brane swelling.
F. In-Vivo Biocompatibility
The animals were bred and treated in accordance with the
Swiss Federal Veterinary Office guidelines and were kept in spe-
cific pathogen-free animal facility. Experiments were approved
by “Dipartimento della Sanitá e Socialitá“ with authorization
number TI-19/2010. Microchips were cleaned and disinfected
with ethanol 70% and placed in sterile PBS (Gibco) for 24 h to
stabilize the membrane. An Air Pouch (AP) was created by sub-
cutaneous injection of sterile air in the back of male C57BL/6
mice at day 1 (5 mL) and day 3 (3 mL): this procedure cre-
ates a cavity of 1.5 cm diameter and 0.5 cm height. At day 6,
mice were anesthetized with isoflurane 4%, shaved and locally
sterilized with Betadine solution; the sterile microchips were
implanted and the cavity sutured with Vicryl 6.0 (Provet AG).
As a control of local inflammation, bacterial lipopolysaccha-
ride (LPS) (50 ) (LabForce AG) was injected daily
into the cavity for the last 2 weeks of the 30 days of the ex-
periment. As negative control APs were generated in the ab-
sence of any surgical procedure. As further control commercial
chips (DATAMARS)were injected through sterile needle. After
30 days, the microchips were removed. The cavity was rinsed
with 0.5 mL of PBS (Gibco) and the liquid collected and cen-
trifuged at 7000 rpm for 10 min at 4 . The concentration of
ATP was determined in the supernatant with ATP determination
kit (Invitrogen). For polymorphonuclear neutrophils detection,
Fig. 8. Calibration line of glucose detection in CA (at a fix potential of
650 mV) of the 1.2 mm WE after electrodeposition of the chitosan/MWCNT
dispersion and after functionalization with GOx. Error bars correspond to the
standard deviation for 3 different measurements (confidence interval 95.4%).
the pellet was resuspended in 0.2 mL RPMI 10% fetal bovine
serum (Gibco) and analyzed at flow cytometer (FACS Canto,
Becton Dickinson) with antibodies specific for CD11b and Gr1,
labelled with allophycocyanin (APC) and fluorescein isothio-
cyanate (FITC, BioLegend), respectively.
IV. CHARACTERIZATION AND TESTS
A. Passive Chip Characterization
1) Measurements of Glucose and Anti-Cancer Drugs: The
characterization of the microfabricated sensor toward detection
of glucose was performed with CA. After the electrodeposition
ofMWCNTs in chitosan and the functionalization of the 1.2 mm
WE with the enzyme GOx, electrodes were tested for glucose
sensitivity with CA at 650 mV. The inset in Fig. 8 reports
the current response of the 1.2 mmWE to repeated injections of
glucose 50 . Well-defined current steps are visible every fur-
ther injection of glucose. The calibration line reported in Fig. 8
is calculated from the evaluation of the current steps, by mea-
suring the difference between the reached current value and the
baseline (corresponding to the current at 0 of glucose). We
obtained a sensitivity of and a LOD
of , which is relevant in many clinical applications
[31], [32]. Many other metabolites of clinical interest (e.g., lac-
tate, glutamate, ATP) can be monitored with our sensing plat-
form, by changing the enzyme that is employed for the electrode
functionalization.
The anti-cancer drugs ETO and MTX were monitored to test
the performance of the sensing platform in CV. CV has been
found to be excellent for the determination of electroactive
drugs in different biological fluids. Many drug compounds have
been determined by voltammetric techniques, as for antibi-
otics, antiemetic, and others [33]. ETO is an anti-cancer drug,
normally used in combination with other chemotherapeutic
agents in the treatment of refractory testicular tumors and as
first line treatment in patients with small cell lung cancer. It is
known from literature that ETO is an electro-active compound
and in CV it gives two well-defined oxidation peaks at around
300 mV and 600 mV (versus Ag AgCl) [34]. Also MTX, an
anti-neoplastic agent for the treatment of secondary progressive
642 IEEE TRANSACTIONS ON BIOMEDICAL CIRCUITS AND SYSTEMS, VOL. 8, NO. 5, OCTOBER 2014
Fig. 9. Cyclic voltammograms of a bare electrode in PBS, in the presence of
MTX 200 and ETO 200 .
Fig. 10. Calibration curve for MTX within the physiological range in PBS,
obtained in CV. Error bars correspond to the standard deviation for 4 different
measurements (confidence interval 95.4%). The inset shows the oxidation peak
currents increasing with the drug concentration.
sclerosis, can be oxidized at a working electrode, through an
irreversible electrode process that gives two oxidation peaks in
CV: at 500 mV and 700 mV (versus Ag AgCl) [35].
Fig. 9 shows the resulting cyclic voltammograms for a bare
electrode (1.2 mm diameter) in PBS and in the presence of
200 ETO and 200 MTX. According to the literature,
the voltammograms show two defined oxidation peaks for ETO
(at 300 mV and 600 mV versus Pt) and two oxidation peaks
for MTX (at 300 mV and 500 mV vesus Pt). With bare elec-
trodes we also performed CVmeasurements to calibrate the sen-
sors for MTX and ETO within the therapeutic range. Fig. 10
shows the dependence of the peak current on MTX concen-
trations. Similar curves were obtained also for ETO (data not
showed). The y-axis values are the oxidation current peaks cen-
tered at 500 mV. The inset in Fig. 10 shows the linear increase
in current of the oxidation peaks at variousMTX concentrations.
Table II summarizes the results in terms of sensitivity per unit
area and limit of detection (LOD), obtained for the two drugs
with a bareWE. For both drugs we obtained LODs that are com-
patible with the physiological ranges reported in the last column
of Table II . These results prove that the sensing platform is ca-
pable to monitor drugs and metabolites within their therapeutic
ranges.
TABLE II
SENSITIVITY, LOD AND THERAPEUTIC RANGES OF MTX AND
ETO DETECTED IN CV WITH A BARE ELECTRODE
Fig. 11. Calibration curve for the temperature sensor (forward and backward
scans), for a temperature range between 35 and 42 .
2) Temperature Sensor: The resistive thermal device (RTD)
consists of a Pt wire of 4 nm width and 93 mm length, with an
average resistivity of 34 at 20 . Pt is commonly used in
the production of resistive thermal devices and it was chosen
because, among other metals employed in RTDs such as Cu
and Ni, Pt represents the best trade-off between linear behavior,
biocompatibility, and higher metal resistivity, which allowed
reducing the sensor sizes [38]. Fig. 11 shows the response of
the Pt-RTD upon different temperatures in PBS. The temper-
ature was first increased from 35 to 42 (forward scan)
and then was inversely changed (backward scan). The Pt-RTD
shows a linear behavior in the physiological temperature range
with an average sensitivity of 0.11 , which is compa-
rable with the theoretical value of 0.13 (that can be
calculated from the temperature coefficient of resistivity for Pt,
). High error bars are due to the low accuracy
of the instrument used to measure the resistivity.
3) pH Sensor: An external reference electrode double junc-
tion in Ag AgCl was used to obtain stable and reproducible
measurements. IrOx is a well-known biocompatible material al-
ready used in the creation of implantable electrodes [29]. The
OCP of an IrOx film changes in a predictable manner according
to the solution pH. Fig. 12 shows the calibration of the pH
sensor in the squared version measured in the pH range from
5 to 9. The pH of the buffer solution was continuously con-
trolled with an external pH meter and we measured the cor-
responding OCP for the forward scan (pH from 5 to 9) and
for the backward scan (pH from 9 to 5). The inset of Fig. 12
shows the OCP measurements versus time. In the considered
range, the potential changes linearly with increasing pH, with
a sensitivity of for the forward scan, and
for the backward scan. These sensitivity
values are quite close to the values reported in [29], and our
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Fig. 12. Open circuit potential of the IrOx coated electrode to different pH. The
inset shows the OCP measurements versus time. The OCP steps correspond to
different pH levels.
Fig. 13. The measured output waveform of the rectifier, regulator and the
waveform generator for cyclic voltammetry when the inductive link is used for
powering the system.
sensors shows good stability and reproducibility. The pH sensor
showed in Fig. 6 is slightly different to the one used for these
measurements (circular electrode with a diameter of 300 ,
instead of a squared electrode), but we do not
expect to obtain significantly different results.
B. Active Chip Characterization
We also performed some preliminary measurements by im-
plementing together in an autonomous microsystem the main
building blocks, which are: (i) the inductive coil; (ii) the power
management IC; (iii) the interface IC to control and readout
the biosensor; and (iv) the biosensor. This active autonomous
system was tested in CV to measure the oxidation peaks of the
anti-cancer drugs MTX and ETO. The measured voltage wave-
form at the output of the rectifier, regulator and the waveform
generator are shown in Fig. 13when the powermanagement unit
and the inductive link provides power to the waveform gener-
ator and readout circuits. The readout and waveform generator
circuits were used for CV measurements on MTX and ETO.
CVs were registered at room temperature under aerobic con-
ditions by applying the triangular waveform with the slope of
82 mV/sec to the WE and a fixed voltage to the RE. The main
oxidation peak position and its location (in voltage) for both
TABLE III
COMPARISON OF THE OXIDATION PEAK OF ETO AND MTX MEASURED
WITH THE COMMERCIAL EQUIPMENT AND THE ACTIVE CHIP
measurements are summarized in Table III. The measured oxi-
dation current peak location and value has less than 7% discrep-
ancy between our active chip and the Autolab potentiostat. More
details on these measurements with the autonomous system can
be found in [39].
V. BIOCOMPATIBLE PACKAGING
Potential sources of inflammation for implantable devices
are attributed to the materials, shape and sizes of the devices
[7]. MWCNTs were entrapped in a chitosan matrix to prevent
toxicity due to the nano-particle nature of the MWCNTs and
residues of the catalysts as well. To prevent leaking of po-
tential hazardous substances and the corrosion of electronic
components in contact with biologic fluids, a 10- coating
of Parylene C was employed [27]. For an implantable sensor,
the development of a biocompatible packaging is essential for
permitting wound healing, and ensuring prolonged sensor func-
tionality. Most of biocompatible packaging from literature [40]
require a mold (e.g., for packaging in PDMS) or the application
of an additional membrane (e.g., polycarbonate membrane)
that results in many manipulation steps that could affect the
final biocompatibility grade. In this work, we assembled the
passive sensing platform, with the blocks for power supply and
the IC for the measurement, which were previously described
(Section II), into an implantable compact device. Then, we
developed a biocompatible packaging using an epoxy enhanced
polyurethane membrane tested for the first time by Yu et al. [2].
Moreover the porosity of the membrane controls the passage
of analytes to the electrodes, without the need of an additional
membrane.
Fig. 14 shows photograph of the device after the me-
chanical milling, the deposition of Parylene C, the electrode
functionalization and the membrane dip-coating. This device
was implanted in mice for 30 days to test the biocompatibility,
which will be showed in the paragraph V.B, after the membrane
in-vitro characterization, presented in the next paragraph.
A. Membrane Characterization and Measurements
In-vitro characterization of the membrane was performed on
carbon-paste SPEs, in order to assess the optimized number of
membrane layers and to understand the membrane effect on
enzyme activity. After the functionalization with MWCNTs
and GOx, electrodes were covered with 1-2-3 layers of the
membrane, and finally tested for glucose sensitivity with CA
at 650 mV. Fig. 15 reports the effect of the curing tem-
perature and membrane thickness on sensor sensitivity. The
high temperature effect on biosensors without any membrane
was investigated, showing a decrease in sensitivity probably
due to a partial enzyme denaturation. However LOD was
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Fig. 14. Photograph of the final assembled device.
Fig. 15. Heat and membrane thickness effects on the sensor sensitivity (Error
bars: standard error of three different SPE-based biosensors).
lower after the curing compared to the case of a
SPE-MWCNT/GOx biosensor , due to a reduction
of the standard deviation of the background signal (data not
shown). Last columns in Fig. 15 show that the application of
one layer of membrane does not significantly change sensor
performances, probably due to a not homogeneous coating.
Two and three layers decrease the sensor sensitivity and in-
crease the LOD ( and respectively),
but are the best trade-off between the decrease of sensitivity
and a homogeneous cover. We also performed CA with our
microfabricated passive chip. Working electrodes of 1.2 mm
diameter, modified with MWCNTs in chitosan and GOx, were
covered with 2-3 layers of the membrane. All the chips were
tested for glucose sensitivity with CA at 650 mV, and the
sensitivity was then compared. Without any membrane we
obtained a sensitivity of and a LOD
of . With 2 layers of the membrane we obtained a
lower sensitivity but a lower LOD
due again to reduction of the standard deviation
of the background signal. Similarly to SPE based sensor, the
addition of a third membrane layer does not significantly affect
the sensor performances: with 3 layers we obtained a sensitivity
of and a LOD of . The long
term stability of the coated biosensor was evaluated by CA
for glucose sensitivity on SPEs for 40 days. The work in [41]
reported a long term stability of 24 days using the same SPE
Fig. 16. Long term stability of a biosensor coated by 2 membrane layers (Error
bars: standard error of two measurements on each day).
and GOx immobilized by adsorption onto MWCNT-working
electrode. Fig. 16 shows that with two layers of epoxy enhanced
polyurethane membrane the sensitivity slightly decreases with
respect to time; the relative variation is equal to 28% after
35 days. The decrease of the sensor sensitivity is mainly due
to the partial degradation of the enzyme activity over the time,
and it represents the major challenge in the development of a
long-term implantable sensor. However, as reported in [42],
[43], it is possible to take into account the decrease in sensitivity
with a one-point calibration method, thus increasing the sensor
accuracy during long-time measurements.
B. Biocompatibility In-Vivo Tests
In order to investigate the in-vivo biocompatibility of the im-
plantable sensor, we subcutaneously implanted four prototypes
in mice for 30 days. At the end of the period, the implant site
was washed with PBS, and levels of ATP and neutrophils in
the elution liquid were quantified to follow the local inflamma-
tory response. Changes in ATP concentration and changes in
neutrophils percentage give information on the local cell death
and on the status of tissue inflammation, respectively. Fig. 17
reports ATP and neutrophil variations in the liquid collected
from the implant site. ATP and neutrophil levels were also eval-
uated for a commercial chip (DATA MARS), in case of in-
duced inflammation (LPS) and for the negative control (mice
with AP). In flow citometry, for the negative controls, the neu-
trophils level is barely detectable, while there is still a small
amount of extracellular ATP due to mechanical stress created
by fluid collection. Data from both neutrophil infiltration and
ATP concentration suggest that the membrane provides a quite
good biocompatible coverage. Furthermore, only in case of in-
duced inflammation (LPS), local redness and swelling were vis-
ible. After 30 days, ATP and neutrophil levels are comparable
with the negative control (AP), as well as for the commercial
chip, and significantly lower than the positive control (LPS),
proving that after 30 days the host seems to accept the implant.
Unfortunately, a cell layer covered the surface of the sensing
platform. Future steps will be the evaluation of the effect of
this cell layer on sensing performances and the application of
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Fig. 17. ATP concentrations (nM) and percentages of neutrophils recovered
from APs treated as indicated.
an anti-fouling agent on top of the membrane in order to reduce
the cell adhesion.
VI. CONCLUSIONS
In this work we showed the assembly into a fully-implantable
device of a microfabricated sensing platform, power and data
transmission and ICs. We show the design of each block of the
device from a system level: readout circuits were designed to
control and readout the biosensor array powered by the power
management IC. The power is transferred to the battery-less
implanted device though an optimized inductively coupled
link over 30 mm distance. We finally describe the assembled
integrated device intended to test the biocompatibility of the
material used for the microfabrication. An epoxy enhanced
polyurethane membrane was used to cover the device to en-
sure biocompatibility. An in-vitro characterization proved that
the membrane is capable to retain enzyme activity up to 35
days. In-vivo experiment in mice proved that, after 30 days
of implant, the membrane promotes the integration of the
sensor with the surrounding tissue, as demonstrated by the
low inflammation levels at the implant site. The system has
been also tested for the measurement of the two anti-cancer
drugs MTX and ETO, with CV method. The CV measurements
which are reported in the Section IV-B showed that the redox
peaks corresponding to the two compounds estimated in terms
of maximum current and the voltage position are measured
with less than 7% discrepancy, compared to the commercial
equipment.
Future work will focus on the assembly of the ICs, the coil
and the sensing platform in a fully-working prototype. More-
over, the problem of interfering compounds in biological fluids
will be investigated through the employment of an additional
membrane. The prototype will be employed for in-vivo mea-
surements in mice inside the cage. In in-vivo testing we will also
face other issues, such as the screening of interfering substances
and the sensor selectivity.
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